XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.26.1

Stock Based Compensation | 6 Months Ended
--- | ---
Mar. 29, 2026
Share-Based Payment Arrangement [Abstract] |
Stock Based Compensation | Note 6 - Stock Based Compensation Restricted Stock, Market-Based Shares and Restricted Stock Units issued to Directors, Officers and Employees The following table summarizes the status of Optex Systems Holdings’ aggregate non-vested restricted stock and restricted stock units, and market-based shares: Schedule of Aggregate Non-vested Restricted Stock and Restricted Stock Units Granted and Market-based Shares
|  | Restricted Stock Units |  |  | Weighted Average Grant Date Fair Value |  |  | Restricted Shares |  |  | Weighted Average Grant Date Fair Value |  |  | Market-Based Shares |  |  | Weighted Average Grant Date Fair Value |
Outstanding at September 29, 2024 |  |  | 66,500 |  |  | $ | 5.56 |  |  |  | 60,000 |  |  | $ | 2.20 |  |  |  | - |  |  | $ | - |
Granted |  |  | 39,000 |  |  |  | 6.35 |  |  |  | 32,800 |  |  |  | 9.29 |  |  |  | - |  |  |  | - |
Vested |  |  | (24,000 | ) |  |  | 5.17 |  |  |  | (60,000 | ) |  |  | 2.20 |  |  |  | - |  |  |  | - |
Forfeited |  |  | (7,500 | ) |  |  | 5.19 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Outstanding at September 28, 2025 |  |  | 74,000 |  |  | $ | 6.11 |  |  |  | 32,800 |  |  | $ | 9.29 |  |  |  | - |  |  | $ | - |
Granted |  |  | 2,000 |  |  |  | 14.15 |  |  |  | 16,700 |  |  |  | 16.06 |  |  |  | 67,500 |  |  |  | 10.06 |
Vested |  |  | - |  |  |  | - |  |  |  | (32,800 | ) |  |  | 9.29 |  |  |  | - |  |  |  | - |
Forfeited |  |  | (9,000 | ) |  |  | 6.16 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Outstanding at March 29, 2026 |  |  | 67,000 |  |  | $ | 6.35 |  |  |  | 16,700 |  |  | $ | 16.06 |  |  |  | 67,500 |  |  | $ | 10.06 |
Restricted Stock Units On May 1, 2024, the Company granted an aggregate of 39,000 restricted stock units to 11 employees under the Company’s 2023 Equity Incentive Plan (the “2023 Plan”). As of the grant date, assuming a 7.7% forfeiture rate based on expected turnover across the three years, the aggregate value of the restricted stock units is $258 thousand which will be amortized across the three-year period on a straight-line basis. The restricted stock units will vest at a rate of 33.33% annually on the anniversary date of the grant and any unvested restricted stock units will be forfeited if employment terminates prior to the relevant vesting date. On June 4, 2024 there was an additional grant of 500 restricted stock units to one employee with a fair value of $4 thousand. The 500 restricted stock units will vest 100% on the anniversary date of the grant and will be forfeited if employment terminates prior to the relevant vesting date. On July 3, 2024 there was an additional grant of 1,000 restricted stock units to one employee with a fair value of $7 thousand. The 1,000 restricted stock units will vest 100% on the anniversary date of the grant and will be forfeited if employment terminates prior to the relevant vesting date. During the twelve months ended September 28, 2025, there were 24,000 shares vested and 7,500 shares forfeited under the 2023 Plan. On May 1, 2025, the Company granted an aggregate of 39,000 restricted stock units to 11 employees under the 2023 Plan. As of the grant date, assuming a 12.8% forfeiture rate based on expected turnover across the three years, the aggregate value of the restricted stock units is $216 thousand which will be amortized across the three-year period on a straight-line basis. The restricted stock units will vest at a rate of 33.33% on each of the first, second and third anniversaries of the date of the grant and any unvested restricted stock units will be forfeited if employment terminates prior to the relevant vesting date. On October 15, 2025, the Company granted 1,000 restricted stock units to one employee under the 2023 Plan. As of the grant date, the fair value of the restricted stock units is $15 thousand which will be amortized across the twelve-month period on a straight-line basis. The restricted stock units will vest on October 15, 2026 and any unvested restricted stock units will be forfeited if employment terminates prior to the vesting date. On January 5, 2026, the Company granted 1,000 restricted stock units to one employee under the 2023 Plan. As of the grant date, the fair value of the restricted stock units is $13 thousand which will be amortized across the twelve-month period on a straight-line basis. The restricted stock units will vest on January 5, 2026 and any unvested restricted stock units will be forfeited if employment terminates prior to the vesting date. On January 5, 2026 and January 23, 2026, there were 3,000 and 6,000 restricted stock units, respectively, that were forfeited due to employee departures prior to the vesting date. As of March 29, 2026, there were 67,000 unvested restricted stock units outstanding. Restricted Shares On April 30, 2020, the Board of Directors voted to increase the annual board compensation for the three independent directors from $22,000 to $36,000 with an effective date of January 1, 2020, in addition to granting 100,000 shares of restricted stock to each independent director which vest at a rate of 20% per year (20,000 shares) each January 1st through January 1, 2025. The total fair value for the 300,000 shares was $525 thousand based on the stock price of $1.75 as of April 30, 2020. On each of January 1, 2021, January 1, 2022, and January 1, 2023, 60,000 of the restricted director shares vested. On February 16, 2023, 40,000 of the unvested restricted shares were forfeited and cancelled when one of the independent directors departed the Board. On May 9, 2023, the Board of Directors approved a grant of 40,000 shares of restricted stock to independent board member Dayton Judd. The shares vest 50% on each of December 31, 2023 and January 1, 2025. As of the grant date, the fair value of the shares was $124 thousand, to be amortized on a straight-line basis through December 31, 2024. The Company amortizes the grant date fair value to stock compensation expense on a straight-line basis across the five5-year and two2-year vesting periods beginning on April 30, 2020 and May 9, 2023, respectively. As of December 29, 2024, there were 60,000 of such unvested restricted shares outstanding which vested January 1, 2025. On November 5, 2024, the Board approved the following Board compensation for the three independent directors, effective January 1, 2025: (a) a cash payment of $44,000, and (b) $66,000 in restricted stock awarded under the 2023 Plan, with 100% vesting on January 1, 2026, the share price calculated on the basis of the 10-day VWAP, and the number of shares rounded up to the nearest 100 shares. The restricted stock award was made on November 5, 2024 and consisted of 7,600 shares of restricted stock for each independent director. The total fair value for the 22,800 shares was $185 thousand based on the stock price of $8.10 as of November 5, 2024. As of December 28, 2025, there were 22,800 of such unvested restricted shares outstanding, which vested on January 1, 2026. On August 11, 2025, the Board approved an award to Chad George of 10,000 shares of restricted stock under the Company’s 2023 Plan pursuant to his employment as Optex Systems Holdings, Inc.’s President. The total fair value for the 10,000 shares was $120 thousand based on the stock price of $12.00 as of August 12, 2025. As of December 28, 2025, there were 10,000 of such unvested restricted shares outstanding which vested on January 1, 2026. On November 4, 2025, the Board approved the following Board compensation for the three independent directors, effective January 1, 2026: (a) a cash payment of $44,000, and (b) $66,000 in restricted stock awarded under the 2023 Plan, with 100% vesting on January 1, 2027, the share price calculated on the basis of the 10-day (immediately preceding and including the date of grant) VWAP, and the number of shares rounded up to the nearest 100 shares. The restricted stock award was made on November 4, 2025 and consisted of 4,000 shares of restricted stock for each independent director. The total fair value for the 12,000 shares was $201 thousand based on the stock price of $16.74 as of November 4, 2025. As of March 29, 2026, there were 12,000 of such unvested restricted shares outstanding, which will vest on January 1, 2027. On December 5, 2025, the Board approved the annual director compensation for Danny Schoening, effective January 1, 2026: (a) $44,000 in cash and (b) $66,000 in restricted stock granted as of December 5, 2025 under the Company’s 2023 Plan, with 100% vesting on January 1, 2027, the share price calculated on the basis of the 10-day (immediately preceding and including the date of grant) VWAP, and the number of shares rounded up to the nearest 100 shares. The restricted stock award was made on December 5, 2025 and consisted of 4,700 shares of restricted stock. The total fair value for the shares was $67 thousand based on the stock price of $14.33 as of December 5, 2025. As of March 29, 2025, there were 4,700 of such unvested restricted shares outstanding, which will vest on January 1, 2027. On January 1, 2026, 32,800 restricted shares vested, and as of March 29, 2026, there were 16,700 restricted shares remaining to vest on January 1, 2027. Market-Based Shares Effective December 18, 2025, the Board approved a grant of 50,000 and 17,500 market-based shares to Chad George, the Company’s President and CEO, and Karen Hawkins, the Company’s Chief Financial Officer, respectively, pursuant to the Company’s 2023 Plan. Each market-based share represents a contingent right to receive one share of the Company’s common stock. The market-based shares vest in five equal increments if, in each case and during a performance period beginning on December 18, 2025 and ending on September 29, 2030, the average VWAP per share of common stock over a 30 consecutive trading day period equals or exceeds $17.54, $21.05, $25.26, $30.31, or $36.37. The fair value of the market-based shares as of the grant date is $679 thousand to be amortized over the estimated service period based on a Monte Carlo simulation. As of March 29, 2026, there were 67,500 market-based shares remaining to vest. The assumptions and results for the Monte Carlo simulation employed for the market-based shares are as follows: Schedule of Assumptions and Results for the Monte Carlo Simulation for the Market-based Shares
|  | Assumptions |
Performance Period Start |  |  | 12/18/2025 |
Performance Period End |  |  | 9/30/2030 |
Time steps in simulation |  |  | 1,205 |
Time steps per year |  |  | 252 |
Common share price at valuation date (1) |  | $ | 13.60 |
Dividend yield (2) |  |  | 0.0 | %
Volatility (annual) (3) |  |  | 52.5 | %
Risk-free rate (annual) (4) |  |  | 3.64 | %
Cost of equity (5) |  |  | 12.0 | %
|  | Tranche 1 |  |  | Tranche 2 |  |  | Tranche 3 |  |  | Tranche 4 |  |  | Tranche 5 |
Number of Market-Based shares in the Tranche (6) |  |  | 13,500 |  |  |  | 13,500 |  |  |  | 13,500 |  |  |  | 13,500 |  |  |  | 13,500 |
Fair Value of One Market-Based share (7) |  | $ | 12.08 |  |  | $ | 11.16 |  |  | $ | 10.12 |  |  | $ | 9.02 |  |  | $ | 7.90 |
Total Fair Value of Tranche |  | $ | 163,051 |  |  | $ | 150,633 |  |  | $ | 136,669 |  |  | $ | 121,713 |  |  | $ | 106,662 |
Derived Service Period (Years) (7) |  |  | 0.66 |  |  |  | 1.12 |  |  |  | 1.58 |  |  |  | 2.01 |  |  |  | 2.37 |
| (1) | Closing price of OPXS shares on the Valuation Date, as obtained via S&P Capital IQ.
| (2) | Expected dividends provided by management.
| (3) | Based on historical volatility of OPXS and comparable public companies.
| (4) | Interest rate for US Treasury commensurate with the market-based shares holding period, as of the Valuation Date, as obtained via S&P Capital IQ.
| (5) | Estimated cost of equity for OPXS as of the Valuation Date.
| (6) | Based on the terms of the Market-Based shares agreement issued by the Company on December 18, 2025 and effective December 18, 2025.
| (7) | Based on Monte Carlo simulation.
Stock Based Compensation Expense Equity compensation is amortized based on a straight-line basis across the vesting or service period as applicable. The recorded compensation costs for restricted shares granted and restricted stock units and market-based shares awarded as well as the unrecognized compensation costs are summarized in the table below: Schedule of Unrecognized Compensation Costs
|  | Stock Compensation |
|  | (thousands) |
|  | Recognized Compensation Expense |  |  | Unrecognized Compensation Expense |
|  | Three months ended |  |  | Six months ended |  |  | As of period ended |
|  | March 29, 2026 |  |  | March 30, 2025 |  |  | March 29, 2026 |  |  | March 30, 2025 |  |  | March 29, 2026 |  |  | September 28, 2025 |
Restricted Shares |  | $ | 60 |  |  | $ | 40 |  |  | $ | 204 |  |  | $ | 99 |  |  | $ | 176 |  |  | $ | 112 |
Performance Shares |  |  | 143 |  |  |  | - |  |  |  | 160 |  |  |  | - |  |  |  | 519 |  |  |  | - |
Restricted Stock Units |  |  | 57 |  |  |  | 32 |  |  |  | 108 |  |  |  | 65 |  |  |  | 263 |  |  |  | 342 |
Total Stock Compensation |  | $ | 260 |  |  | $ | 72 |  |  | $ | 472 |  |  | $ | 164 |  |  | $ | 958 |  |  | $ | 454 |
The unrecognized compensation expense for restricted shares, market-based shares and restricted stock units as of March 29, 2026, is expected to be recognized over a weighted-average period of 0.8 years, 1.4 and 2.2 years, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration